Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Hypercholesterolemia in the U.S.

Analysis of: Vical Begins Phase 1 Trial Of DNA Vaccine Against H5N1 Pandemic Influenza (www.medicalnewstoday.com)
I'm looking forward to the results of the H5N1 clincial trial.  This might improve the world's chances of avoiding a pandemic like the one in 1918.
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US (www.pipelinereview.com)
With so many other medications available to help control diabetes, who will risk prescribing Avandia? 
August 28, 2007
Medical Tourism
Analysis of: American's Gamble for Bargain Surgery Abroad (www.medpagetoday.com)
Medical Tourism is purely linked to lower costs for the same procedure.Most of these relate to 1)Small elective surgeries 2) Non-Urgent Cardiac and Non-Cardiac Procedures and Operations 3)Cosmetic Procedures 4)Dental and Vision corrective procedures 5)Radiologic Procedures(Diagnostic and Ther...
August 28, 2007
Angio-seal today-SS
Analysis of: St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device (www.medicalnewstoday.com)
The key implications remain 1)Safety 2)Efficacy 3)Cost 4)Complications e)Outcome analysis
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US (www.pipelinereview.com)
New black box warning for Avandia makes the warning for CHF risk stronger. The information about an increase in Coronary Ischemia events is not addressed by this change in labeling. Physicians wait for FDA to drop the other shoe.
August 13, 2007
not always
Analysis of: Older and cheaper pills just fine for diabetes (www.reuters.com)
1-diabetics are an extremely diverse group of people 2-co-morbidities, stage of disease, and the pancreatic reserve all govern the ideal regimen for a certain patient 3-the more options we have, the better equipped we are to help more patients 4-glycemic control is not the only decisive factor when...
Analysis of: HMOs to start ad blitz against Medicare cuts (news.yahoo.com)
Medicare Advantage plans provide a large revenue source for the Insurance carriers while increasing the cost to the Medicare funds. In a time where Medicare is looking at becoming insolvent, giving additional money to Insurance carriers to make providing care to the patients  makes no sense ...
Michael Davidson, MD, FACC, Director, Preventive Cardiology
Michael Davidson, MD, FACC, Director, Preventive Cardiology
The University of Chicago
Analysis of: FDA Advisory Committee on The Cardiovascular Ischemic/thrombotic Risks of Rosiglitzone (www.ncbi.nlm.nih.gov)
It appears from the breifing documents that the FDA has concerns about the CV safety of Avandia. They appear to be less concerned about the CV safety of Actos but both drugs are associated with an increase risk of heart failure. It is unknown how the Advisory Committee will vote but based on the available...
Analysis of: AMA warns of threat to doctors' pay (pressherald.mainetoday.com)
The cliffhanger we physicians see at the end of each year is fast approaching. Medicare cuts are looming and much higher than previous years. I am barely hanging on to my practice as it is, 10% cuts will be the end of it. I contact the legislators dutifully when the AMA asks and when ACP asks. The legislators...
Analysis of: UPDATE: Novartis Wins FDA OK For Alzheimer's Drug Patch (money.cnn.com)
Been down this road before when Exelon was released. We had used a lot of Exelon before for our patients, but tolerance was a problem. As anticipated many had nausea and vomiting. We switched back to Aricept. Product is the same. Interesting concept, but marketing will be key to the success of this...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next71 to 80 of 146

Analytics


Generated at 2009-01-07T19:00:58.307